Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.49 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776035 | 0.82 | HRH3 (0.62) | ATML3MBTL1KDM4EPOLBHRH3 | |
| SCHEMBL1929274 | 0.79 | LTA4H (0.48) | LTA4HATML3MBTL1PTGS2PSMB1 | |
| SCHEMBL2326590 | 0.78 | KDM4E (0.66) | LTA4HPTGS2KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL18410137 | 0.77 | HRH3 (0.56) | ATML3MBTL1KDM4EPOLBHRH3 | |
| SCHEMBL1927451 | 0.77 | ESR1 (0.56) | L3MBTL1KDM4EPOLBGAASMN1; SMN2 | |
| SCHEMBL1929134 | 0.77 | LTA4H (0.52) | LTA4HPTGS2PSMB1PSMB5PSMB2 | |
| SCHEMBL1928729 | 0.76 | KCNH2 (0.51) | LTA4HPTGS2KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL13849416 | 0.76 | KDM4E (0.59) | LTA4HPSMB1PSMB5PSMB2KDM4E | |
| SCHEMBL1927551 | 0.76 | KCNH2 (0.51) | LTA4HPTGS2KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL6042831 | 0.76 | MAOB (0.57) | PSMB1PSMB5PSMB2KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | disclosed |
| US-7956084-B2 | Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2011-06-07 | — | — | US | disclosed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | LTA4H 1678/4885ATM 3449/4885L3MBTL1 4086/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | LTA4H 2569/4885ATM 3543/4885L3MBTL1 4397/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | LTA4H 1678/4885ATM 3449/4885L3MBTL1 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.